These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11377343)

  • 1. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
    Chang SS; Reuter VE; Heston WD; Gaudin PB
    Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
    Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
    Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
    Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
    Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.
    Chang SS; Reuter VE; Heston WD; Gaudin PB
    Urology; 2001 Apr; 57(4):801-5. PubMed ID: 11306418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer.
    Ross JS; Sheehan CE; Fisher HA; Kaufman RP; Kaur P; Gray K; Webb I; Gray GS; Mosher R; Kallakury BV
    Clin Cancer Res; 2003 Dec; 9(17):6357-62. PubMed ID: 14695135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
    Sweat SD; Pacelli A; Murphy GP; Bostwick DG
    Urology; 1998 Oct; 52(4):637-40. PubMed ID: 9763084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical role of prostate-specific membrane antigen (PSMA).
    Chang SS; Heston WD
    Urol Oncol; 2002; 7(1):7-12. PubMed ID: 12474535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
    Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
    Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.
    Ananias HJ; van den Heuvel MC; Helfrich W; de Jong IJ
    Prostate; 2009 Jul; 69(10):1101-8. PubMed ID: 19343734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
    Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
    Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of monoclonal antibodies in the imaging of prostate cancer.
    Yao D; Trabulsi EJ; Kostakoglu L; Vallabhajosula S; Joyce MA; Nanus DM; Milowsky M; Liu H; Goldsmith SJ
    Semin Urol Oncol; 2002 Aug; 20(3):211-8. PubMed ID: 12215974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
    Jia L; Jiang Y; Michael CW
    Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
    Murphy GP; Elgamal AA; Su SL; Bostwick DG; Holmes EH
    Cancer; 1998 Dec; 83(11):2259-69. PubMed ID: 9840525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
    Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
    Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
    Gong MC; Chang SS; Sadelain M; Bander NH; Heston WD
    Cancer Metastasis Rev; 1999; 18(4):483-90. PubMed ID: 10855791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.
    Wolf P; Freudenberg N; Bühler P; Alt K; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U
    Prostate; 2010 Apr; 70(5):562-9. PubMed ID: 19938014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells.
    Barren RJ; Holmes EH; Boynton AL; Misrock SL; Murphy GP
    Prostate; 1997 Jan; 30(1):65-8. PubMed ID: 9018338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
    Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
    Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.